MKM Partners Upgrades Amylin Pharmaceuticals (AMLN) to Neutral
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
MKM Partners upgraded Amylin Pharmaceuticals (NASDAQ: AMLN) from Sell to Neutral, price target raised from $10.50 to $22.00.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $23.77 yesterday.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $23.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
